RxDoctor Payments Data

David Rose, MD

Pulmonary Disease · Saint Louis, MONPI 1982133211

Payments from drug & device makers

$2,786in general payments, 2019–2025

Across 138 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$389
  • Merck$273
  • GSK$262
  • Sanofi$211
  • Regeneron Healthcare Solutions, Inc.$197
  • Grifols USA, LLC$165
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,68696%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,786 in reported general payments places this provider in the 50th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$111,233
Medicare patients
354
Services billed
1,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate11$136,900
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$75,363
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,756
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$8,553
Breo ElliptaFluticasone/Vilanterol15$7,236
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,726
SymbicortBudesonide/Formoterol Fumarate12$2,889
Albuterol Sulfate HfaAlbuterol Sulfate76$1,866
Ipratropium Bromide26$663
Azithromycin15$355
Prednisone33$155
Fluticasone Propionate12$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$110$142,62623 claims
GSKTrelegy Ellipta, Breo Ellipta$262$82,599115 claims
AstraZenecaBreztri Aerosphere, Symbicort$389$12,64528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →